CNBC   |  July 01, 2013

Onyx Rejects Amgen's Takeover Bid

Onyx is essentially putting itself up for sale to the highest bidder, reports CNBC's David Faber, although it did reject an unsolicited bid from Amgen because the board believed it undervalued the company.

Share This:

Sorry, we do not have a transcript available for this video at this time.